Latest news

• Solid performance for Merck KGaA in "transformation year"

  Sales and profits on track amid job cuts and restructuring. Germany's Merck KGaA successfully navigated a tricky path in 2012 as it kept sales and profits on target, despite ... The restructuring programme is already yielding results in terms of Merck's

• Bayer pins hopes on five potential blockbusters

  to 39.8bn for 2012. ... This helped overcome a decline in sales of the Yaz contraceptive franchise, which lost patent exclusivity during 2012.

• Mylan agrees $1.6bn deal to buy Agila injectables unit

  yesterday to discuss the deal and Mylan's fourth-quarter results. ... The agreement comes as Mylan reported record financial results in 2012, with revenues up 14 per cent to $6.8bn on the back of 600 product launches around the world, and

• UCB CEO: Patient info more important than transparency

  Speaking at the presentation of the Belgium-based pharma company's 2012 financial results, Doliveux (pictured) said the ongoing debate over transparency was of little interest outside the UK, and that

• Actavis sales rise but profits slump as Lipitor effect recedes

  2012 in its first set of results since the merger. ... Actavis stopped selling its generic atorvastatin last month because of the "significant decline in the US market for this product in 2012", said Actavis chief financial officer Todd Joyce on the